Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 4, Pages 1113
Publisher
MDPI AG
Online
2018-04-11
DOI
10.3390/ijms19041113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biological Role and Therapeutic Targeting of TGF-β 3 in Glioblastoma
- (2017) Katharina Seystahl et al. MOLECULAR CANCER THERAPEUTICS
- Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
- (2017) Richard E. Kast et al. Oncotarget
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
- (2016) Michael Weller et al. Oncotarget
- Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor
- (2016) N. Sumru Bayin et al. NEOPLASIA
- Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta
- (2015) Laurent-Olivier Roy et al. INVESTIGATIONAL NEW DRUGS
- Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate
- (2015) JUAN SEPULVEDA-SANCHEZ et al. Oncology Letters
- Transforming growth factor-β pathway activity in glioblastoma
- (2015) Karl Frei et al. Oncotarget
- Three-dimensional Nuclear Telomere Architecture Is Associated with Differential Time to Progression and Overall Survival in Glioblastoma Patients
- (2015) Macoura Gadji et al. NEOPLASIA
- Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies
- (2014) Kathryn M. Field et al. CANCER
- Emerging treatment strategies for glioblastoma multiforme
- (2014) S. K. Carlsson et al. EMBO Molecular Medicine
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Smad-independent pathway involved in transforming growth factor β1-induced Nox4 expression and proliferation of endothelial cells
- (2014) Nora Y. Hakami et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Transforming growth factor-beta and its implication in the malignancy of gliomas
- (2014) Laurent-Olivier Roy et al. Targeted Oncology
- Active CREB1 Promotes a Malignant TGF 2 Autocrine Loop in Glioblastoma
- (2014) L. Rodon et al. Cancer Discovery
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
- (2013) David M. Peereboom et al. NEURO-ONCOLOGY
- Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β
- (2012) Matthew E. Hardee et al. CANCER RESEARCH
- Infiltration of glioma cells in brain parenchyma stimulated by radiation in the F98/Fischer rat model
- (2012) Guillaume Desmarais et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009
- (2012) T. A. Dolecek et al. NEURO-ONCOLOGY
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
- (2011) Dagmar Beier et al. Molecular Cancer
- Trabedersen to target transforming growth factor- : when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)
- (2011) W. Wick et al. NEURO-ONCOLOGY
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
- (2010) Roger Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma
- (2009) Silvia Peñuelas et al. CANCER CELL
- Lysosomotropic drugs inhibit maturation of transforming growth factor-β
- (2008) Julie Basque et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search